AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma-Reference-Cited by-同舟云学术

AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

Published:2015-07-09 Issue:2 Volume:126 Page:160-166
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Noy Ariela¹^ORCID,Lee Jeannette Y.²,Cesarman Ethel³,Ambinder Richard⁴,Baiocchi Robert⁵,Reid Erin⁶,Ratner Lee⁷,Wagner-Johnston Nina⁷,Kaplan Lawrence⁸

Affiliation:

1. Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical Center, New York, NY;

2. University of Arkansas Medical Center, Little Rock, AR;

3. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY;

4. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD;

5. Division of Hematology, Ohio State Medical Center, Columbus, OH;

6. University of California San Diego, Moores Cancer Center, La Jolla, CA;

7. Division of Oncology, Washington University School of Medicine, St. Louis, MO; and

8. Department of Medicine, University of California San Francisco, San Francisco, CA

Abstract

Key Points We report the first dedicated prospective study in HIV-Burkitt lymphoma demonstrating safety and efficacy in a multi-institutional setting. We offer a new therapeutic option by modifying an existing regimen and making it much less toxic.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/2/160/1390043/160.pdf

Reference30 articles.

1. Long-term remissions following one and two-dose chemotherapy for African lymphoma.;Burkitt;Cancer,1967

2. Burkitt’s lymphoma in adults: a retrospective study of 46 cases.;Ostronoff;Nouv Rev Fr Hematol,1992

3. Treatment of Burkitt’s lymphoma in HIV-positive patients.;Straus;Biomed Pharmacother,1996

4. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin’s lymphoma: analysis of AIDS Clinical Trials Group protocol 142—low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor.;Straus;J Clin Oncol,1998

5. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection.;Kaplan;N Engl J Med,1997

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management;Blood Reviews;2024-01

2. Clinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus-associated Burkitt lymphoma: the Central and Western China AIDS lymphoma league 002 study (CALL-002 study);Infectious Agents and Cancer;2023-12-05

3. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial;The Lancet Haematology;2023-12

4. China Anti-Cancer Association (CACA) guidelines for holistic integrative management of lymphoma (version 2022);Holistic Integrative Oncology;2023-11-27

5. How I treat secondary CNS involvement by aggressive lymphomas;Blood;2023-11-23